ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Insights from 2024 ASCO® GU Annual Meeting

E. Efstathiou

Bladder Cancer Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

Yale Cancer Center

I. Kim

AUA Advanced Prostate Cancer Guidelines: 2023 Update

Robert Dreicer

Testosterone Suppression and Recovery in Patients With Advanced Pros…

Benjamin L. Maughan

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

2024 ESMO Annual Meeting Insights Hub

R. Dreicer

ACP 2024 Insights: Cancer of Unknown Primary

Insights from 2024 ACP Annual Meeting

S. Brondfield

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence for Or…

2024 ASCO® Annual Meeting Insights Hub

J. Hafron

Visible vs. Invisible Cancers - The Genomics and Natural History

Laurence Klotz

Enhanced Diagnostics in Prostate Cancer: PSA and Beyond in 2024

Penn Medicine Abramson Cancer Center

D. Lee

Palliative Medicine in Cancer Patients

Houston Methodist

E. De Leon

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

Urothelial Carcinoma: New Developments

Weill Cornell Medicine Oncology & Hematology

C. Sternberg

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

University of Colorado Cancer Center

T. Flaig

Review of mCRPC Updates From ESMO 2024

The View on GU | with Lalani & Wallis

A. A. Lalani, C. Wallis

The Future of Lung Cancer Care

Yale Cancer Center

M. Davies

No Role to Continue ICI Beyond Progression: CONTACT-03 & TiNivo-2 Ph…

Dana-Farber Cancer Institute

B. McGregor

Treatment (De)Intensification in RCC

International Urology Cancer Summit - IUCS

S. Kumar Pal

Trastuzumab Deruxtecan Approval for Metastatic HER2+ Bladder Cancer

UCSF School of Medicine

V. Koshkin

Differences Between Urologists and Medical Oncologists in the Manage…

Northwestern Medicine Oncology and Hematology

W. Catalona